Risk factors
GeneDx Holdings (WGS) risk factors
Item 1A of every GeneDx Holdings Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks9 new12 dropped14 reworded
New risks add impairment exposure, FDA Breakthrough Device uncertainty for ExomeDx and GenomeDx, and expanded privacy and AI concerns.
Filed Feb 23, 2026 - FY2024 10-K risk factors72 risks
GeneDx faces significant financial risks with an accumulated deficit of $1.4 billion as of December 31, 2024. The company relies entirely on production facilities in Gaithersburg, Maryland, for its exome and whole genome sequencing tests. The business is heavily dependent on maintaining compliance with stringent FDA, CLIA, and HIPAA regulations.
Filed Feb 20, 2025